The Delhi High Court has prohibited Natco Pharma from producing and selling the cancer drug Olaparib, marketed as 'BRACANAT' or under any other name, until further notice. The court's decision came in response to a lawsuit by Kudos Pharmaceuticals, which claimed that Natco was infringing on its patent for Olaparib. The court found Natco's challenge to the patent's validity unconvincing, leading to the injunction. Natco had sought to revoke Kudos' patent only after the lawsuit was filed, despite no previous opposition to it.
